Recommendations of the Spanish Menopause Society on the consumption of omega-3 polyunsaturated fatty acids by postmenopausal women. (September 2017)

• Record Type: Journal Article
• Authors: Sánchez-Borrego, Rafael; von Schacky, Clemens; Osorio, María José Alonso; Llaneza, Plácido; Pinto, Xavier; Losa, Fernando; Navarro, Mª Concepción; Lubián, Daniel; Mendoza, Nicolás
• Is Part Of: Maturitas. Volume 103(2017)
• Page Start: 71
• Page End: 77
• Publication Date: 2017-09
• Subjects: Omega-3 polyunsaturated fatty acids -- Menopause -- Cardiovascular disease; Climacteric -- Periodicals; Menopause -- Periodicals; Climacteric -- Periodicals; Geriatrics -- Periodicals; Menopause -- Periodicals; Middle Aged -- Periodicals; Climatère -- Périodiques; Ménopause -- Périodiques; Climacterium; Climacteric; Menopause; Electronic journals; Periodicals; 612.66
• DOI: 10.1016/j.maturitas.2017.06.028
• Languages: English
• ISSNs: 0378-5122

Abstract

Highlights: Long-chain omega-3 polyunsaturated fatty acids (LCO3-PUFAs) have antiarrhythmic effects, reduce blood pressure and decrease triglycerides. LCO3-PUFAs improve some rheumatic processes, particularly rheumatoid arthritis. Correction of LCO3-PUFA deficiency appears to improve depressive and psychotic symptoms. LCO3-PUFA intake has not been found to be associated with an increased risk of any type of cancer. We need more data to confirm the benefit of LCO3-PUFAs in the relief of menopause symptoms and osteoporosis. Abstract: The consumption of long-chain omega-3 polyunsaturated fatty acids (LCO3-PUFAs) has shown a great variety of beneficial effects, including cardiovascular, metabolic and inflammatory effects, which make them interesting for the postmenopausal woman. Because LCO3-PUFAs could be effective and safe during this period, a panel of experts from the Spanish Menopause Society met to establish a set of recommendations for their use in postmenopausal women based on the best available evidence. The decrease in triglycerides is the most consistent effect observed with LCO3-PUFAs (at doses greater than 3 g/day). In addition, LCO3-PUFAs have antiarrhythmic effects, reduce blood pressure, improve depressive and psychotic symptoms, and do not increase the risk of cancer. However, further studies are needed to confirm the benefit of LCO3-PUFAs in the relief of menopause symptoms and osteoporosis.